PET/CT Variants and Pitfalls in Head and Neck Cancers Including Thyroid Cancer.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 2. Blood Rev. 2015 Nov;29(6):417-25. doi: 10.1016/j.blre.2015.06.003. Epub 2015 Jun 17. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Adams HJ(1), Nievelstein RA(2), Kwee TC(2). Author information: (1)Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: h.j.a.adams@gmail.com. (2)Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. Bone marrow involvement in lymphoma may have prognostic and therapeutic consequences. Bone marrow biopsy (BMB) is the established method for the evaluation of the bone marrow. (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) plays an important role in lymphoma staging, but its value in the assessment of the bone marrow and whether it can replace BMB is still a topic of debate and investigation. The purpose of this scientific communication is to provide an evidence-based overview about the opportunities and limitations of BMB and FDG-PET in the evaluation of the bone marrow in patients with lymphoma. This article first reviews the basic properties, opportunities and limitations of BMB and bone marrow FDG-PET, and then focuses on the clinical utility of BMB and bone marrow FDG-PET in three major lymphoma subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Copyright © 2015 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.blre.2015.06.003